Moberg Pharmas Year-end report 2021
THE MEDICAL PRODUCTS AGENCY IN SWEDEN WILL BE REFERENCE MEMBER STATE IN MOBERG PHARMA´S EUROPEAN REGISTRATION APPLICATIONPERIOD (FULL-YEAR 2021) · EBITDA SEK -17.1 million (-18.4) * · Operating profit (EBIT) SEK -19.7 million (-21.0) * · Profit after tax SEK -16.2 million (-18.4) * · Total profit SEK 7.4 million (-20.0) ** · Diluted earnings per share SEK 0.17 (-1.05) ** · Cash and cash equivalents amounted to SEK 102.7 million (19.3) FOURTH QUARTER (OCT-DEC 2021) · EBITDA SEK -4.2 million (-5.3) * · Operating profit (EBIT) SEK -4.9 million (-6.0) * ·